XML 86 R30.htm IDEA: XBRL DOCUMENT v3.20.1
Agreement with Eli Lilly and Company (Tables)
 12 Months Ended
Dec. 31, 2019
Agreement with Eli Lilly and Company  
Summary of deferred revenue included in the Company’s balance sheets

 

 

 

 

 

 

 

 

 

December 31, 

(in thousands)

 

2019

 

2018

Deferred revenue, beginning of period

 

$

26,725

 

$

 —

Up-front payment

 

 

 —

 

 

25,000

Attributed premium on the proceeds from Lilly’s investment in the Company

 

 

 —

 

 

1,725

Research and development support billing

 

 

2,000

 

 

 —

Revenue from research and development arrangement recognized

 

 

(6,347)

 

 

 —

Total deferred revenue, end of period

 

 

22,378

 

 

26,725

Less: Deferred revenue, current portion

 

 

(6,428)

 

 

(4,989)

Deferred revenue, non-current portion

 

$

15,950

 

$

21,736